dpp4 vs sglt2 vs glp-1 Type 2 Diabetes: The Effects of Different Antidiabetic Drug Classes on Mortality SGLT-2 inhibitors, GLP-1 receptor agonists,

7g of fiber per serving

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), approved for diabetes and obesity, have shown promise in modulating reward-related brain pathways, suggesting potential benefits in the management of AUD

However, most (59%) of same those employers say their cost for the drugs has exceeded expectations

Introduction Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are key therapies for type 2 diabetes and obesity, regulating blood glucose by mimicking endogenous GLP-1

Note: Anti-Obesity GLP-1s Wegovy and Zepbound, Anti-Diabetes GLP-1s Ozempic and Mounjaro Source: IQVIA MAAS Patient Behavior Library Tool